Stock NVRO NEVRO CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Nevro Corp.

Equities

NVRO

US64157F1030

Market Closed - Nyse
Other stock markets
 04:00:05 2024-04-23 pm EDT 		5-day change 1st Jan Change
12.81 USD +4.40% Intraday chart for Nevro Corp. +0.87% -40.47%
Apr. 15 RBC Lowers Price Target on Nevro to $16 From $18, Keeps Sector Perform Rating MT
Apr. 11 Mizuho Adjusts Price Target on Nevro to $16 From $20, Maintains Neutral Rating MT

Evolution of the average Target Price on Nevro Corp.

Price target over the last 5 years

History of analyst recommendation changes

e493def3059157d0c48c0.lJU0q9Y0p2xvfPlxLpyuOC60QHuhltl3KoMH4Ow2jwQ.rPx52ZN5llknK5MlZOibbUiMcCrY_YAjeO520ZtH60Pj2AbqknjtQQAklg~605a8582f4c3091bb0232e38fbf50869

Analyst Recommendations on Nevro Corp.

RBC Lowers Price Target on Nevro to $16 From $18, Keeps Sector Perform Rating MT
Mizuho Adjusts Price Target on Nevro to $16 From $20, Maintains Neutral Rating MT
Citigroup Cuts Price Target on Nevro to $16 From $18, Maintains Neutral Rating MT
Wells Fargo Adjusts Price Target on Nevro to $17 From $20, Maintains Equal-Weight Rating MT
Baird Cuts Price Target on Nevro to $19 From $23, Maintains Neutral Rating MT
Oppenheimer Downgrades Nevro to Perform From Outperform, Removes $35 Price Target MT
RBC Lowers Price Target on Nevro to $18 From $20, Keeps Sector Perform Rating MT
RBC Downgrades Nevro to Sector Perform From Outperform, Cuts Price Target to $20 From $23 MT
Truist Securities Adjusts Price Target on Nevro to $23 From $22, Maintains Hold Rating MT
Canaccord Genuity Downgrades Nevro to Hold From Buy, $23 Price Target MT
Truist Securities Adjusts Price Target on Nevro to $17 From $18.50, Keeps Hold Rating MT
Morgan Stanley Cuts Price Target on Nevro to $18 From $23, Calls Q4 Guidance 'Wary,' Keeps Equalweight Rating MT
BofA Cuts Price Target on Nevro to $17 From $28, Keeps Underperform Rating MT
Citigroup Adjusts Price Target on Nevro to $21 From $24, Maintains Neutral Rating MT
Truist Securities Adjusts Nevro's Price Target to $25 From $27, Keeps Hold Rating MT
Morgan Stanley Adjusts Price Target on Nevro to $23 From $29, Maintains Equalweight Rating MT
Wells Fargo Adjusts Price Target on Nevro to $23 From $27, Maintains Equalweight Rating MT
Oppenheimer Adjusts Nevro Price Target to $35 From $40, Maintains Outperform Rating MT
JMP Securities Adjusts Nevro's Price Target to $40 From $75, Keeps Market Outperform Rating MT
Baird Adjusts Nevro's Price Target to $23 From $26, Keeps Neutral Rating MT
RBC Lowers Price Target on Nevro to $33 From $39 Amid 2023 Guidance Cut, Maintains Outperform Rating MT
Truist Securities Adjusts Nevro's Price Target to $27 From $30, Keeps Hold Rating MT
RBC Trims Price Target on Nevro to $39 From $40, Maintains Outperform Rating MT
JPMorgan Cuts Price Target on Nevro to $28 From $40, Maintains Neutral Rating MT
Citigroup Adjusts Price Target on Nevro to $27 From $37, Keeps Neutral Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
17
Last Close Price
12.79 USD
Average target price
17.73 USD
Spread / Average Target
+38.65%
High Price Target
40 USD
Spread / Highest target
+212.74%
Low Price Target
14 USD
Spread / Lowest Target
+9.46%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Nevro Corp.

RBC Capital Markets
Mizuho Securities
Citigroup
Wells Fargo Securities
Baird
Oppenheimer
Truist Securities
Canaccord Genuity
Morgan Stanley
BofA Securities
JMP Securities
JPMorgan Chase
Piper Sandler
Jefferies & Co.
Wolfe Research
SVB Leerink
UBS
OTR Global
William Blair & Co.
Redburn

Ratings for Nevro Corp.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. NVRO Stock
  4. Consensus Nevro Corp.